P3I
CLBT icon

Progeny 3 Inc’s Cellebrite CLBT Stock Holding History

Progeny 3 Inc’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.2M Buy
2,000,000
+871,871
+77% +$11.5M 1.51% 24
2026
Q1 		$15.5M Buy
+1,128,129
New +$17M 0.83% 27

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Progeny 3 Inc's CLBT Position: Q2 2026 in Review

Progeny 3 Inc increased its Cellebrite (CLBT) stake by 77% in Q2 2026, buying an estimated $11.5M and bringing the position to 2,000,000 shares worth $29.2M. The position accounts for 1.51% of the portfolio, ranked #24.

Progeny 3 Inc first reported a position in CLBT in Q1 2026 and has held it in 2 quarters since. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Progeny 3 Inc held 2,000,000 shares of Cellebrite worth $29.2M as of Q2 2026.
  • Progeny 3 Inc bought 871,871 Cellebrite shares in Q2 2026, an estimated $11.5M.
  • Cellebrite made up 1.51% of Progeny 3 Inc's portfolio in Q2 2026, its #24 holding.
  • Progeny 3 Inc first reported a position in Cellebrite in Q1 2026 and has held it in 2 quarters since.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Progeny 3 Inc's 13F filing for Q2 2026, filed 14 Aug 2026.